Results 111 to 120 of about 837,409 (288)

De novo design of epitope-specific antibodies via a structure-driven computational workflow

Nature Communications
Accurate modeling of antibody-antigen complex structures holds significant potential for advancing biomedical research and the design of therapeutic antibodies.
Fandi Wu, Yu Zhao, JiaXiang Wu, Biaobin Jiang, Bing He, Longkai Huang, Chenchen Qin, Yang Xiao, Fan Yang, Rubo Wang, Ningqiao Huang, Huaxian Jia, Yuyi Liu, Houtim Lai, Tingyang Xu, Fang Wang, Zihan Wu, Yidong Song, Shaoning Li, Wei Liu, Yu Rong, Peilin Zhao, Jianhua Yao   +22 more
doaj   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Antibody targeted nanoparticles for imaging and therapy of cancer

, 2010
The central hypothesis for this thesis is that antibody-targeted superparamagnetic iron oxide nanoparticles (SPIONs) can be used for diagnosis and therapy of cancer.
Vigor, K.L.
core  

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Antibody-dependent enhancement of HIV-1 infection.

, 2007
Antibody-dependent enhancement (ADE) is the process by which virus-specific antibodies enhance entry or replication of a virus, leading to increased infection and the potential to exacerbate disease progression or severity. In terms of HIV infection, ADE
Willey, S., Willey, Suzanne
core  

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source

Characterisation of subtype C HIV-I envelope glycoproteins and their recognition by llama antibody fragments

, 2009
Subtype C HIV-1 is currently responsible for the majority of new infections in the world, particularly in parts of Africa where the adult prevalence rate is as high as 15%.
Koh, W.W.-L.
core  

IsAb: a general in silico protocol for antibody design

, 2021
The design of therapeutic antibodies has attracted a large amount of attention over the past ten years. Antibodies are widely used to treat many diseases due to their high efficiency and low risk of adverse events.
Liang, Tianjian
core  

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source

Nanodesigner: resolving the complex-CDR interdependency with iterative refinement

Journal of Cheminformatics
Camelid heavy-chain only antibodies consist of two heavy chains and single variable domains (VHHs), which retain antigen-binding functionality even when isolated.
Melissa Maria Rios Zertuche, Şenay Kafkas, Dominik Renn, Magnus Rueping, Robert Hoehndorf   +4 more
doaj   +1 more source